Industry News
BioDioem eyes vision drug market
Melbourne biopharma BioDiem (ASX:BDM) has entered the race to develop a treatment for the ophthalmic disorder, age-related macular degeneration (AMD), by taking a licence for a Russian-developed peptide therapeutic that has shown high promise in an Australian clinical trial. [ + ]
Healthy ASX listing for Sunshine Heart
Sunshine Heart (ASX: SHC) listed on the ASX today at AUD$0.60 -- 10 cents above its issue price. But at time of writing the cardiac company's shares had slipped slightly lower to AUD$0.57. [ + ]
Pharmas desperately need academic guidance: Cohen
The University of Dundee's Sir Philip Cohen believes that pharmaceutical companies desperately need the help of academic labs, as drug development requires more and more knowledge about biological mechanisms to specifically target drugs. [ + ]
Pharmaxis breathing easier after positive Phase II results
Pharmaxis (ASX:PXS) investors will be breathing easy after the company announced a positive result from its Phase II clinical trial of Bronchitol, its lead compound for treating the chronic lung disorder bronchiectasis. [ + ]
Boston's Athena Diagnostics to market Bionomics epilepsy test
South Australian biopharma Bionomics(ASX:BNO) announced today it has licensed Boston company Athena Diagnostics to market its test for severe myoclonic epilepsy of infancy (SMEI) to neurologists in North America and Japan. [ + ]
Iliad hits homer with first drug
Unlisted Melbourne drug-development company Iliad Chemicals has reported promising results from a pre-clinical trial of its first anti-cancer drug, developed with its proprietary Multicore drug-synthesis technology. [ + ]
Combio 2004 - be altruistic, scientists told
Eminent burns surgeon Fiona Wood has opened the ComBio 2004 meeting in Perth with an appeal to scientists' altruism. [ + ]
Genetic basis for metabolic diseases detected
Oxford geneticists have closed in on the genetic basis for risk factors of metabolic diseases such as hypertension, obesity and diabetes.
[ + ]Peptech ready for growth
Peptech (ASX: PTD) is keenly awaiting the day the Centocor decision is handed down by the arbitrators. [ + ]
NHMRC sets five-year moratorium on organ xenotransplantation
The National Health and Medical Research Council has recommended a five-year moratorium on any clinical research into animal-to-human whole organ transplants in Australia. [ + ]
Labor promises $28 million in graduate subsidies and education
Labor has announced a $22 million four-year Smart Partnerships program under which 800 graduates would receive subsidised industry placements, and $6 million would be earmarked for educational programs aimed at supporting business ideas with commercial potential. [ + ]
Avexa lists on ASX
Amrad (AML) spin-off Avexa (ASX: AVX) listed on the ASX this morning with trading hovering around AUD$0.265. [ + ]
GTG in $18m deal with Genzyme
Genetic Technologies (ASX: GTG) has taken the first step in forming a strategic alliance with US-based biotech Genzyme by granting a licence for its non-coding DNA patents that will bring in more than AUD$18 million in revenue over the next 11 years. [ + ]
Psivida spins out diagnostic specialist
Perth nanotechnology company Psivida (ASX: PSD) has spun out an Australia-based diagnostics company, AION Diagnostics. [ + ]
BTF granted US patent for 'Bioballs'
Private Sydney-based biotech BTF has been granted a US patent for its BioBall quality-control product. [ + ]
